New preclinical findings highlight Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene - often called…
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed…
UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically…
NEW YORK and PARIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rarecells, a pioneer in liquid biopsy technologies, today presented new…
De nouvelles données démontrent que l’association avec l’amivantamab réduit significativement les mutations courantes de résistance à l’EGFR et au MET…
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in…
Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology…
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Sept. 08, 2025…
Dr. Lockwood brings more than 20 years of experience driving revenue growth and establishing global partnerships for manufacturing and research…